126 related articles for article (PubMed ID: 38363020)
21. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
22. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion.
Liu R; Tian B; Gearing M; Hunter S; Ye K; Mao Z
Proc Natl Acad Sci U S A; 2008 May; 105(21):7570-5. PubMed ID: 18487454
[TBL] [Abstract][Full Text] [Related]
23. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
24. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
[TBL] [Abstract][Full Text] [Related]
25. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.
Shimon I; Hinton DR; Weiss MH; Melmed S
Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064
[TBL] [Abstract][Full Text] [Related]
26. CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.
Wang F; Zhao W; Gao Y; Zhou J; Li H; Zhang G; Guo D; Xie C; Li J; Yin Z; Zhang J
J Exp Clin Cancer Res; 2019 Jul; 38(1):286. PubMed ID: 31272499
[TBL] [Abstract][Full Text] [Related]
27. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
28. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development.
Kuchenbauer F; Theodoropoulou M; Hopfner U; Stalla J; Renner U; Tonn JC; Low MJ; Arzt E; Stalla GK; Páez-Pereda M
Mol Cell Endocrinol; 2003 Sep; 207(1-2):13-20. PubMed ID: 12972179
[TBL] [Abstract][Full Text] [Related]
29. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
30. Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1.
Faraoni EY; Camilletti MA; Abeledo-Machado A; Ratner LD; De Fino F; Huhtaniemi I; Rulli SB; Díaz-Torga G
J Endocrinol; 2017 Mar; 232(3):535-546. PubMed ID: 28096433
[TBL] [Abstract][Full Text] [Related]
31. Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Sun SS; Zhou X; Huang YY; Kong LP; Mei M; Guo WY; Zhao MH; Ren Y; Shen Q; Zhang L
Mol Cancer; 2015 Dec; 14():213. PubMed ID: 26690371
[TBL] [Abstract][Full Text] [Related]
32. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
[TBL] [Abstract][Full Text] [Related]
33. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK; Jirawatnotai S; Trudeau T; Kuzyk C; Wierman ME; Kiyokawa H; Gutierrez-Hartmann A
Endocrinology; 2018 Jun; 159(6):2421-2434. PubMed ID: 29726995
[TBL] [Abstract][Full Text] [Related]
34. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
[TBL] [Abstract][Full Text] [Related]
35. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.
Jiang XB; Hu B; He DS; Mao ZG; Wang X; Song BB; Zhu YH; Wang HJ
BMC Cancer; 2015 Sep; 15():644. PubMed ID: 26400193
[TBL] [Abstract][Full Text] [Related]
36. Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development.
Wang X; Ma L; Ding QY; Zhang WY; Chen YG; Wu JH; Zhang HF; Guo XL
Endocr Relat Cancer; 2021 Jun; 28(7):433-448. PubMed ID: 33974557
[TBL] [Abstract][Full Text] [Related]
37. Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.
García-Barrado MJ; Blanco EJ; Iglesias-Osma MC; Carretero-Hernández M; Catalano-Iniesta L; Sanchez-Robledo V; Carretero M; Herrero JJ; Carrero S; Carretero J
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29104246
[TBL] [Abstract][Full Text] [Related]
38. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
39. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
[TBL] [Abstract][Full Text] [Related]
40. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]